---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-010212"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2022-03-15T23:59:59+00:00"
generated_at: "2026-06-26T22:49:42.803862+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Imara reports FY2021 net loss $51.4M; interim Phase 2b data expected April 2022

## Summary
- Net loss $51.4M ($2.37 per share) vs $49.2M ($3.53 per share) in FY2020; cash $90.3M at Dec 31, 2021.
- Phase 2b SCD and beta-thalassemia trials fully enrolled; interim data from both trials expected first week of April 2022.
- FDA required change of Ardent SCD trial primary endpoint to annualized VOC rate; conduct unchanged.
- Added HFpEF indication for tovinontrine; Phase 2 trial dosing expected Q2 2022; pipeline expanded with IMR-261.
- FY2022 guidance: R&D $60-65M, G&A $13-15M; cash runway through Q1 2023.

## SEC filing metadata
- accession: 0001564590-22-010212
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2022-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000156459022010212/0001564590-22-010212-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000156459022010212/imra-8k_20220315.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-010212
- JSON: https://secwatch.observer/filing/0001564590-22-010212.json
- Plain text: https://secwatch.observer/filing/0001564590-22-010212.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.